右半结肠癌淋巴结清扫范围的5年生存随访:RELARC随机对照试验
RELARC试验5年随访纳入995例右半结肠癌患者,比较CME与D2清扫的远期生存。两组5年OS(HR 0.74,95%CI 0.51-1.07,P=0.105)和CSS(HR 0.72,95%CI 0.49-1.06,P=0.091)无显著差异,但CME在III期、pN2及脉管侵犯亚组中可能获益。
要点
- 标准D2清扫5年肿瘤学结局与CME相当,仍应作为右半结肠癌标准术式。
- III期患者CME可能改善5年OS(HR 0.58)和CSS(HR 0.59)。
- pN2及脉管侵犯患者接受CME与更优生存相关,交互作用显著。
核心结论
- 标准D2清扫在5年随访中提供与CME相当的肿瘤学结局。
- CME可能改善III期、尤其pN2状态患者的5年结局,并可能使脉管侵犯患者获益。
研究设计与样本
- 共入组1072例 eligible 患者,995例纳入改良意向性治疗分析。
- 主要终点为5年OS,次要终点为5年CSS;试验注册号NCT02619942。
主要发现
- CME组与D2组5年OS无显著差异(HR 0.74,95%CI 0.51-1.07,P=0.105)。
- 两组5年CSS无显著差异(HR 0.72,95%CI 0.49-1.06,P=0.091)。
- III期患者CME组5年OS(HR 0.58,95%CI 0.37-0.93,P=0.023)和CSS(HR 0.59,95%CI 0.37-0.94,P=0.028)更优。
- pN2患者CME组5年OS和CSS均为HR 0.25(95%CI 0.11-0.57,P=0.001),交互作用显著。
- 脉管侵犯患者CME组OS HR 0.34(95%CI 0.17-0.70,交互P=0.009),CSS HR 0.32(95%CI 0.15-0.67,交互P=0.008)。
临床怎么用
- 右半结肠癌根治术应常规行标准D2淋巴结清扫,无需全部行CME。
- 对III期尤其pN2或伴脉管侵犯患者,可考虑CME以潜在改善远期生存。
局限性
- 原文摘要未报告亚组分析的多重比较校正及具体局限性描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the overall survival (OS) and cancer-specific survival (CSS) of right-sided colon cancer patients undergoing CME versus D2 surgery after 5 years of follow-up, and to assess the heterogeneity of treatment effectiveness of CME between different subgroups. SUMMARY BACKGROUND DATA: The 3-year result of the Radical Extent of lymphadenectomy of Laparoscopic Right Colectomy for colon cancer (RELARC) trial showed that standard D2 dissection should be performed in right-sided colon cancer patients. In patients with lymph node metastasis, complete mesocolic excision (CME) showed potentially favorable results. METHODS: The parallel, open label, randomized controlled trial was conducted between January, 2016 to December, 2019 in 17 hospitals in China. Of a total of 1072 eligible patients enrolled, 995 patients were included in the modified intention-to-treat analysis. In the present study, the primary outcome was 5-year OS and the secondary outcome was 5-year CSS. The trial is registered with ClinicalTrials.gov (Identifier: NCT02619942). RESULTS: 995 patients were included in the final analysis. There was no significant difference between the 5-year OS (HR: 0.74, 95%CI: 0.51-1.07, P=0.105) or CSS (HR: 0.72, 95%CI: 0.49-1.06, P=0.091) in the CME and D2 groups. CME appears to improve 5-year outcomes in patients with stage III disease (OS: HR: 0.58, 95% CI: 0.37-0.93, P=0.023; CSS: HR: 0.59, 95% CI: 0.37-0.94, P=0.028), particularly in those with pN2 (OS: HR: 0.25, 95% CI: 0.11-0.57, P=0.001; CSS: HR: 0.25, 95% CI: 0.11-0.57, P=0.001), where a statistically significant interaction was identified. Patients with lymphovascular invasion also demonstrated favorable outcomes with CME with significant interaction effect (OS: HR: 0.34, 95% CI: 0.17-0.70; interaction P=0.009; CSS: HR: 0.32, 95% CI: 0.15-0.67, interaction P=0.008). CONCLUSION: The standard D2 dissection provides oncologic outcomes comparable to CME on the 5-year follow-up. However, CME seems to improve 5-year outcomes in patients with stage III, particularly those with pN2 status, and may confer benefit in patients with LVI.
引用
- Li K, Li H, Wu A, et al. Long-Term Survival on Extent of Lymphadenectomy for Right-Sided Colon Cancer: Five-Year Follow-up Results of a Randomized Controlled Trial (RELARC Trial). Ann Surg. 2025. PMID: 40938728. doi:10.1097/SLA.0000000000006941
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。